AIDS Treatment News logo      

December 27, 2009

Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH

"Central fat accumulation remains one of the most distressing but least understood metabolic complications, with very limited management options. Several studies have reported that recombinant Human Growth Hormone (rHGH) can reduce central visceral adipose tissue (VAT), although earliest studies at higher doses (4-6 mg/day) were associated with significant toxicity. Additionally, any benefit seemed dependent on maintaining treatment, and the optimal dose remained to be established.

"It was important to see the 3-years results from a study from the Massachusetts General Hospital, presented by Steven Grinspoon, carried out in people with reduced growth hormone (GH) secretion (peak GH <7.5 ng/mL). ..."


Read more in HIV Treatment Bulletin, November/December, 2009.

0 comments: